Skip to main content

Peer Review reports

From: Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)

Original Submission
10 Jun 2015 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
16 Oct 2015 Editorially accepted
27 Oct 2015 Article published 10.1186/s12885-015-1825-5

You can find further information about peer review here.

Back to article page